0001140361-26-015801.txt : 20260421 0001140361-26-015801.hdr.sgml : 20260421 20260421070040 ACCESSION NUMBER: 0001140361-26-015801 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260421 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260421 DATE AS OF CHANGE: 20260421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 26876704 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 ef20071051_8k.htm 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  April 21, 2026
 
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
000-19125
 33-0336973
(Commission File No.)
(IRS Employer Identification No.)

2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
 
Registrant’s telephone number, including area code: (760) 931-9200

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading symbol
Name of each exchange on which
registered
Common Stock, $.001 Par Value
  
“IONS”
   The Nasdaq Stock Market, LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
  Emerging growth company ☐               
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 7.01
Regulation FD Disclosure.
 
On April 21, 2026, Ionis Pharmaceuticals, Inc.  (“Ionis,” “we,” “us” or “our company”) issued a press release announcing additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (“AxD”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
 
Item 8.01
Other Events.
 
On April 21, 2026, we announced additional positive results from the pivotal study of zilganersen in children and adults living with AxD, a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology annual meeting, build on previously reported positive topline data and provide a more comprehensive view of treatment effect across multiple clinically meaningful domains.

The study met its primary endpoint in individuals ≥5 years of age, with zilganersen 50 mg demonstrating statistically significant and clinically meaningful stabilization of gait speed as assessed by the 10-Meter Walk Test (10MWT), compared to control at Week 61. The 10MWT is a commonly used measure of gross motor function in neurologic disease. New data from the Gross Motor Function Measure-88 (GMFM-88), a well-established motor endpoint, supports the primary outcome of the study by demonstrating that treatment with zilganersen may improve gross motor function in younger children (2-4 years of age), compared to control. Key secondary endpoint results from patient/caregiver-and clinician-reported outcome assessments consistently favored zilganersen. Zilganersen demonstrated favorable safety and tolerability.

AxD is a rare, genetic, progressive and often fatal neurological condition that is primarily associated with toxic over-production of glial fibrillary acidic protein (“GFAP”). It is estimated to occur in approximately 1 per 1 to 3 million people worldwide. Although symptoms vary depending on age of onset, individuals may experience progressive motor and cognitive dysfunction, a loss of independence and the inability to control muscles for swallowing, airway protection and purposeful movements. Zilganersen is an investigational RNA-targeted medicine designed to reduce overproduction of GFAP, the underlying cause of AxD.

Zilganersen Pivotal Study Results
The pivotal Phase 1-3 study of zilganersen included 53 people with AxD aged 2 to 53 years. Results presented today are from the 60-week double-blind, randomized controlled treatment period of the ongoing trial. Zilganersen met the primary endpoint in patients ≥5 years, resulting in statistically significant and clinically meaningful stabilization of gait speed on the 10MWT at Week 61 compared to control (least square mean difference 33.3%, p=0.041). Additionally, results from the GMFM-88 in children 2-4 years of age support that zilganersen may improve gross motor function at Week 61 compared to control (least square mean difference 22.9 points, nominal1 p=0.034).

1 Nominal p-value; statistical analysis was not controlled for multiplicity

Key secondary endpoints favored zilganersen over control:
Key secondary endpoints evaluated the disease’s heterogeneous presentation through assessments focused on the individual’s most bothersome AxD symptom and their overall health. Across these measures, outcomes favored zilganersen-treated individuals, with more reporting improvement or no change and fewer reporting worsening compared to control.


 •
Most Bothersome Symptom:
In the zilganersen group, 32% of patients rated their most bothersome symptom as “much better” compared to 0% on control. Only 5% of patients receiving zilganersen rated their most bothersome symptom as “much worse” compared to 31% on control.


 •
Patient Global Impression of Severity:
In the zilganersen group, 83% of patients reported improvement or no change in overall disease severity compared to 76% on control. Only 17% of patients receiving zilganersen reported worsening compared to 24% on control.


 •
Patient Global Impression of Change:
In the zilganersen group, 21% of patients reported feeling “much better” overall compared to 0% on control. Only 4% of patients receiving zilganersen reported feeling “much worse” compared to 18% on control.


 •
Clinical Global Impression of Change:
Clinicians rated 75% of patients receiving zilganersen as improved (“a little better”) or “no change” compared to 47% on control. Clinicians rated 25% of patients receiving zilganersen as “a little worse” and 0% as “much worse” compared to 41% as “a little worse” and 12% as “much worse” on control.

Results from additional secondary and exploratory endpoints assessing communication, swallowing, gastrointestinal and autonomic symptoms, support that zilganersen may have a positive impact across AxD symptoms.
 
In an exploratory analysis, zilganersen reduced plasma GFAP levels by 33.6% at Week 61 compared to control (nominal1 p=0.003)2, consistent with its mechanism of targeting GFAP RNA in the central nervous system.
 
Zilganersen demonstrated a favorable safety and tolerability profile, with most adverse events mild or moderate in severity. Serious treatment-emergent adverse events occurred less frequently in the zilganersen group compared to control (37.5% zilganersen 25 mg or 50 mg; 47.1% pooled control).

Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of September 22, 2026.

2 Ratio (zilganersen vs. pooled control) of least-squares geometric mean ratio to baseline 0.664

Forward-Looking Statements
 
This report includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of zilganersen, our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission. Copies of these and other documents are available from Ionis.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits.
Exhibit No.
Description
Press Release dated April 21, 2026.
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Ionis Pharmaceuticals, Inc.
 
 
 
Dated:  April 21, 2026
 By: /s/ Patrick R. O’Neil


Patrick R. O’Neil
 
Executive Vice President, Chief Legal Officer and General Counsel

 
EX-99.1 2 ef20071051_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
FINAL: April 20, 2026

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

– New data highlight potential treatment benefit across multiple AxD symptom domains,
reinforcing zilganersen’s positive impact on people living with this rare, often fatal
neurological disease –

– PDUFA date set for September 22, 2026 –

CARLSBAD, Calif., April 21, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology (AAN) annual meeting, build on previously reported positive topline data and provide a more comprehensive view of treatment effect across multiple clinically meaningful domains.

The study met its primary endpoint in individuals ≥5 years of age, with zilganersen 50 mg demonstrating statistically significant and clinically meaningful stabilization of gait speed as assessed by the 10-Meter Walk Test (10MWT), compared to control at Week 61. The 10MWT is a commonly used measure of gross motor function in neurologic disease. New data from the Gross Motor Function Measure-88 (GMFM-88), a well-established motor endpoint, supports the primary outcome of the study by demonstrating that treatment with zilganersen may improve gross motor function in younger children (2-4 years of age), compared to control. Key secondary endpoint results from patient/caregiver-and clinician-reported outcome assessments consistently favored zilganersen. Zilganersen demonstrated favorable safety and tolerability.

“As a clinician who cares for people living with Alexander disease, I see firsthand the profound and progressive impact this disease has on individuals and their families, particularly given the lack of disease modifying treatment options available today,” said Amy Waldman, M.D., pediatric neurologist and lead investigator for the zilganersen study at Children’s Hospital of Philadelphia. “These results mark a meaningful step forward for families who have waited so long for innovation in Alexander disease. Taken together, the consistent pattern across multiple clinically meaningful measures demonstrates that zilganersen has the potential to change the trajectory of this devastating disease.”

AxD is a rare, genetic, progressive and often fatal neurological condition that is primarily associated with toxic over-production of glial fibrillary acidic protein (GFAP). It is estimated to occur in approximately 1 per 1 to 3 million people worldwide. Although symptoms vary depending on age of onset, individuals may experience progressive motor and cognitive dysfunction, a loss of independence and the inability to control muscles for swallowing, airway protection and purposeful movements. Zilganersen is an investigational RNA-targeted medicine designed to reduce overproduction of GFAP, the underlying cause of AxD.

Zilganersen Pivotal Study Results
The pivotal Phase 1-3 study of zilganersen included 53 people with AxD aged 2 to 53 years. Results presented today are from the 60-week double-blind, randomized controlled treatment period of the ongoing trial. Zilganersen met the primary endpoint in patients ≥5 years, resulting in statistically significant and clinically meaningful stabilization of gait speed on the 10MWT at Week 61 compared to control (least square mean difference 33.3%, p=0.041). Additionally, results from the GMFM-88 in children 2-4 years of age support that zilganersen may improve gross motor function at Week 61 compared to control (least square mean difference 22.9 points, nominal1 p=0.034).

FINAL: April 20, 2026
Key secondary endpoints favored zilganersen over control:
Key secondary endpoints evaluated the disease’s heterogeneous presentation through assessments focused on the individual’s most bothersome AxD symptom and their overall health. Across these measures, outcomes favored zilganersen-treated individuals, with more reporting improvement or no change and fewer reporting worsening compared to control.

  •
Most Bothersome Symptom (MBS):
In the zilganersen group, 32% of patients rated their most bothersome symptom as “much better” compared to 0% on control. Only 5% of patients receiving zilganersen rated their most bothersome symptom as “much worse” compared to 31% on control.


 •
Patient Global Impression of Severity (PGIS):
In the zilganersen group, 83% of patients reported improvement or no change in overall disease severity compared to 76% on control. Only 17% of patients receiving zilganersen reported worsening compared to 24% on control.


 •
Patient Global Impression of Change (PGIC):
In the zilganersen group, 21% of patients reported feeling “much better” overall compared to 0% on control. Only 4% of patients receiving zilganersen reported feeling “much worse” compared to 18% on control.


 •
Clinical Global Impression of Change (CGIC):
Clinicians rated 75% of patients receiving zilganersen as improved (“a little better”) or “no change” compared to 47% on control. Clinicians rated 25% of patients receiving zilganersen as “a little worse” and 0% as “much worse” compared to 41% as “a little worse” and 12% as “much worse” on control.

Results from additional secondary and exploratory endpoints assessing communication, swallowing, gastrointestinal and autonomic symptoms, consistently support that zilganersen may have a positive impact across AxD symptoms.

In an exploratory analysis, zilganersen reduced plasma GFAP levels by 33.6% at Week 61 compared to control (nominal1 p=0.003)2, consistent with its mechanism of targeting GFAP RNA in the central nervous system.

“These data further build on the promise of zilganersen and reinforce its potential to help transform the treatment landscape for people living with Alexander disease,” said Holly Kordasiewicz, Ph.D., executive vice president, chief development officer, Ionis. “The zilganersen results underscore the strength of our technology in targeting the underlying cause of disease, even in complex and heterogenous neurological conditions such as Alexander disease. We are deeply grateful to the patients, families, investigators and broader community who made this research possible. As we look ahead to the FDA action date in September, we remain focused on bringing this potential new treatment to a community that has long been underserved.”

1 Nominal p-value; statistical analysis was not controlled for multiplicity
2 Ratio (zilganersen vs. pooled control) of least-squares geometric mean ratio to baseline 0.664

FINAL: April 20, 2026
Zilganersen demonstrated a favorable safety and tolerability profile, with most adverse events (AE) mild or moderate in severity. Serious treatment-emergent adverse events (TEAEs) occurred less frequently in the zilganersen group compared to control (37.5% zilganersen 25 mg or 50 mg; 47.1% pooled control).

Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of September 22, 2026.

About the Zilganersen Study
The global, multicenter, randomized, double-blind, controlled, multiple-ascending dose (MAD) Phase 1-3 study (NCT04849741) enrolled 54 participants with Alexander disease (AxD) between the ages of 1.5 and 53 years across 13 sites in eight countries. Most participants in the study were children, reflecting the early onset and severe progression of AxD in pediatric populations. Participants were randomized in a 2:1 ratio to receive zilganersen or control for a 60-week double-blind treatment period. The study included two dose cohorts, 25 mg and 50 mg, with the 50 mg dose cohort analyzed as the pivotal dose cohort, with dosing every 12 weeks. At 60 weeks, all eligible participants transitioned into an open-label treatment period, followed by a 120-week open-label, long-term extension treatment period, during which participants in the 25 mg dose cohort moved to the 50 mg dose cohort, and finally a 28-week post-treatment follow-up period. The primary endpoint is percent change from baseline in gait speed as assessed by the 10-Meter Walk Test (10MWT), an assessment of functional mobility, at the end of the double-blind treatment period. Key secondary endpoints include patients' self-identified Most Bothersome Symptom (MBS) Score, change from baseline in Patient Global Impression of Severity (PGIS) Score and Patient Global Impression of Change (PGIC) Score and Clinician Global Impression of Change (CGIC) Score at the end of the double-blind treatment period.

About Zilganersen
Zilganersen is an investigational RNA-targeted medicine being evaluated as a treatment for people with Alexander disease (AxD). Zilganersen is designed to inhibit production of excess glial fibrillary acidic protein (GFAP) that accumulates because of disease-causing variants in the GFAP gene. The U.S. Food and Drug Administration (FDA) granted zilganersen Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations. In addition, the European Medicines Agency (EMA) granted zilganersen Orphan Drug designation.

About Alexander Disease (AxD)
AxD is a rare, progressive and often fatal neurological disease that occurs in approximately 1 per 1 to 3 million people worldwide and affects a type of cell in the brain called astrocytes. Astrocytes have multiple roles in the brain to support neurons and oligodendrocytes, including maintenance of the myelin sheath that protects nerve fibers. AxD is caused by disease-causing variants in the glial fibrillary acidic protein (GFAP) gene and is generally characterized by progressive neurological deterioration resulting in loss of functional mobility, loss of independence and the inability to control muscles for large movements, swallowing and airway protection, though symptoms can vary depending on age of onset. AxD usually leads to death within 14-25 years after symptom onset. There are no approved disease-modifying medicines.

FINAL: April 20, 2026
About Ionis Neurology
Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including SPINRAZA® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA® (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 12 investigational medicines, of which six are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Angelman syndrome, prion disease, multiple system atrophy, Huntington’s disease and Alexander disease, as well as more common conditions such as Alzheimer's disease.

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Ionis Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of zilganersen, our commercial medicines, additional medicines in development and technologies and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals, Inc. SPINRAZA® and QALSODY® are registered trademarks of Biogen. WAINUA™ is a registered trademark of the AstraZeneca group of companies.
EX-101.SCH 3 ions-20260421.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ions-20260421_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 ions-20260421_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information
Apr. 21, 2026
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 21, 2026
Entity File Number 000-19125
Entity Registrant Name IONIS PHARMACEUTICALS, INC.
Entity Central Index Key 0000874015
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 33-0336973
Entity Address, Address Line One 2855 Gazelle Court
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92010
City Area Code 760
Local Phone Number 931-9200
Title of 12(b) Security Common Stock, $.001 Par Value
Trading Symbol IONS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://ionis.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20071051_8k.htm ions-20260421.xsd ions-20260421_lab.xml ions-20260421_pre.xml http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20071051_8k.htm": { "nsprefix": "ions", "nsuri": "http://ionis.com/20260421", "dts": { "inline": { "local": [ "ef20071051_8k.htm" ] }, "schema": { "local": [ "ions-20260421.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "ions-20260421_lab.xml" ] }, "presentationLink": { "local": [ "ions-20260421_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 22 }, "report": { "R1": { "role": "http://ionis.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20260421to20260421", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20071051_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20260421to20260421", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20071051_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://ionis.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001140361-26-015801-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-26-015801-xbrl.zip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end XML 16 ef20071051_8k_htm.xml IDEA: XBRL DOCUMENT 0000874015 2026-04-21 2026-04-21 false 0000874015 8-K 2026-04-21 IONIS PHARMACEUTICALS, INC. DE 000-19125 33-0336973 2855 Gazelle Court Carlsbad CA 92010 760 931-9200 false false false false Common Stock, $.001 Par Value IONS NASDAQ false